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Cytologylittle variation in overall referral to colposcopy and on sensitivity of the entire screening pro-
cess.
Methods: Centre- and age-aggregated data from 72,869 women aged 35e64 years were derived
from 10 organised screening programmes which have piloted HPV screening in Italy since 2012.
Overall colposcopy referral was evaluated as a function of immediate colposcopy referral and
overall CIN2þ detection as a function of the proportion of all CIN2þ detected by immediate
referral (a proxy of cytology’s sensitivity). We fitted additive regression models, adjusted for
centre, age, compliance toHPVretestingand to colposcopy, by generalised estimation equations.
Results: The proportion of HPVþ women directly referred to colposcopy varied across pro-
grammes (20e57%; average 37%) and so did CIN2þ detection (49e94%; average 77%). Overall,
63% (range 41e75%) ofHPVþwere referred to colposcopy either immediately or atHPV repeat.
An absolute 10% increase in immediate colposcopy referral resulted in 4.2% (95%CI: 3.3e5.1%)
increase in overall referral. An absolute 10% increase in cytology’s sensitivity resulted in a 1.1%
(95% CI: 0.1e2.0%) increase in overall CIN2þ detection.
Conclusions: Repeat HPV testing limits the effect of subjectivity of cytology interpretation on
overall referral and sensitivity. These will change only slightly when replacing cytology with
another test if the interval to HPV repeat remains unchanged.
ª 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Human papillomavirus (HPV) DNA testing is more
sensitive than cytology for high-grade cervical intra-
epithelial neoplasia (CIN) but less specific [1], entailing
the need for triaging HPV-positive (HPVþ) women
before referral to colposcopy [2].
HPV DNA testing with cytology triage has been
applied in randomised controlled trials (RCTs). All
these RCTs, despite differences in details, included the
referral of HPVþ women with abnormal cytology (im-
mediate, reflex, triage) to colposcopy and the invitation
of HPV þ women with normal cytology to repeat HPV
DNA testing (second triage). RCTs consistently showed
earlier detection of high-grade CIN [3e5] and reduced
cancer incidence [2] in the HPV arm compared to the
cytology arm, demonstrating the efficacy of this
approach. Also importantly, long-period biopsy rates
were similar in the two arms while the biopsy rate was
doubled with direct referral to colposcopy of all
HPVþ women [2]. Immediate triage by cytology and
genotyping for HPV16/18 with retesting after 1 year for
HPV of women negative to such tests were recom-
mended in 2013 in the United States of America [6].
Despite these achievements, there is still room for
improvements in HPV-based screening and intensive
research is ongoing. The accuracy of cytology inter-
preted with knowledge of HPV status [7,8] and of bio-
markers like genotyping [9], p16 overexpression (alone
[10,11] or combined with Ki67 [12e14]), methylation
of human [15e17] and viral [18e20] genes, and expres-
sion of the E6 viral oncoprotein [21] among
HPVþ women have been studied.
It must be noted that, when retesting is applied, the
overall triage process is done of two phases, one im-
mediate (e.g. reflex cytology) for all HPVþ women anda second one delayed (HPV retesting) for those negative
to immediate triage. HPVþ women can be referred to
colposcopy and have a high-grade CIN detected in
either of the two phases. In order to improve HPV-
based screening protocols, studying the effect of the
overall process is of obvious interest [22]. Indeed, pro-
gramme’s cost and women’s discomfort depend on
overall referral to colposcopy, not just on the referral
due to immediate triage. The sensitivity of the overall
process represents the probability that a precancerous
lesion prevalent at baseline is detected either by the
immediate triage test or by delayed HPV retesting.
These lesions, if missed, would not be detected until the
subsequent screening round and could progress to in-
vasion in the meanwhile. Overall sensitivity therefore is
essential to decide the length of the interval between
completion of the triage process and a new screening
round. Conversely, the sensitivity of the immediate
triage test affects the risk of invasive cancer before HPV
repeat and informs about the safe length of the interval
before such repeat (see Discussion).
If more women are positive to immediate triage (and
referred to immediate colposcopy), then fewer will be
retested (and referred to delayed colposcopy). In addi-
tion, given the high sensitivity of HPV DNA testing, le-
sions not detected by immediate triage are expected to be
detected as a result of retesting, except those which
regress in the interval or occurring in women who missed
or had a falsely negative retest. Therefore, we expect the
two phases to be closely interdependent and that (a)
referral to colposcopy due to the immediate triage test
has a limited impact on overall referral and (b) the
sensitivity of the immediate triage test has very limited
impact, if any, on the sensitivity of the overall process.
To test this hypothesis we used a first extensive survey
of routine HPV-based screening with cytology triage
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interpretation of triage cytology emerged across centres,
we evaluated on over 73,000 women the impact of such
variability on overall referral to colposcopy and overall
detection of high-grade CIN or cancer by the end of the
screening round (i.e. phase 1 þ phase 2).2. Patients and methods
2.1. Organisation of cervical screening and introduction of
HPV-based screening in Italy
The Italian Ministry of Health (MOH) issues rules of
health management, including the list of ‘Essential
Assistance Levels’ (EALs), and funding. However,
health services are under the responsibility of 20 regional
health administrations that must guarantee EALs in
exchange of funds. Organised screening programmes for
cervical cancer have been active in Italy mainly since the
late 1990s and are now part of EALs. Until recently,
programmes regularly invited women aged 25e64 years
for cytology every 3 years. Individual screening data are
systematically registered at a regional/local level. Reg-
ular national surveys are conducted and published
yearly by the national centre for screening monitoring
on behalf of the national MOH [24,25]. For this purpose
standardised tables of aggregated data are collected
from each screening programme. A ‘Programme’ is
hereafter defined as the entity from which aggregated
data were obtained. In general this corresponds to an
organisational unit that manages and coordinates the
different steps of screening, from invitation to diagnostic
assessment and treatment. These units are similarly
organised but their size is variable (Table 1).
During the last 5 years a number of pilot programmes
using the HPV test as primary screening test started in
different areas of Italy. In 2012 an Italian Health
Technology Assessment report [26] based on a system-
atic review of the literature endorsed the superiority of
HPV-based versus cytology-based screening. It also
estimated that the recommended HPV-based screening
protocol would decrease from 422 to 290 euro the
overall cost of screening women from 35 to 64 years of
age, due to the shift from 3- to 5-year intervals (despite
the increase of the cost per screening round, especially
the first with HPV). In 2013, the national MOH rec-
ommended a progressive transition to HPV-based cer-
vical screening with HPV testing every 5 years in women
aged 30e35 to 64 years. Surveys of HPV-based
screening started collecting data in 2013.
2.2. Screening protocol
Italian guidelines recommend stand-alone HPV testing
with cytological triage. Women have samples taken for
both HPV and cytology (either a single sample in liquidmedium or, less commonly, a conventional smear and
another sample for HPV) and are first tested for HPV. If
such test is negative they are returned to a new screening
round. Cytology is prepared and interpreted only for
HPV þ women. If cytology is atypical squamous cells of
undetermined significance or worse women are referred
to colposcopy. If cytology is normal women are rein-
vited for another HPV test after 1 year. If such test is
still positive women are referred for colposcopy.
Otherwise they are returned to a new screening round
(Fig. 1).2.3. Data collection
Nineteen organised screening programmes (out of 119
performing cervical screening) conducted HPV-based
primary screening in 2012.
For each local programme we collected tables
including the number of
a) HPVþ and HPVe women among those screened;
b) HPVþ women referred immediately to colposcopy, having
actually had it and having had CIN or cancer detected on
immediate triage;
c) women invited to HPV retesting after 1 year, who complied,
were still HPVþ, were referred to colposcopy, actually had
it and had a CIN or cancer detected on such occasion.
Tables show women by 5-year age groups and ac-
cording to whether they had been previously screened by
HPV within organised screening. The use of HPV-based
screening in opportunistic activity up to 2012 was
plausibly minimal.
As the protocol entails 1-year repeats of the HPV
test, data on the women invited for a primary HPV test
in 1 year were collected across two years, using a cohort
approach. For women invited to HPV-based screening
during 2012 and screened up to April 2013 tables (a) and
(b) were collected in June/July 2013 and tables (c) in
September 2014.2.4. Data analysis
We included data from 10 programmes that provided
complete data. Nine programmes were excluded
because of lack of sufficient data (mainly age stratifi-
cation, nZ 6), substantial protocol differences (nZ 2),
or extremely small size (n Z 1). Combinations of
screening programme and 5-year age groups were the
statistical units (n Z 60). The few women aged 35e64
years who had been previously screened by HPV were
excluded.
For each centre and 5-year age group we estimated:
- The overall proportion of HPVþ women referred to col-
poscopy as a function of the proportion of HPVþ women
immediately referred to colposcopy because of abnormal
Table 1
Selected features of screening programmes, Italy, 2012e2014.
Programmes Screened
women
% HPVþ
among
screened
women
% of HPVþ
women referred
immediately
to colposcopy
% of
compliance to
1-year HPV
retesting
% HPVþ
at 1-year
retesting
% of CIN2þ
detected at
immediate
referral
Overall %
of screened
women
referred to
colposcopy
Overall
detection of
CIN2þ per
1000 screened
women (n)
Overall % of
HPVþ women
referred to
colposcopy
Overall
detection of
CIN2þ per
100 HPVþ
women
Overall % PPV
for CIN2þ
of colposcopy
referral
Adria 3448 5.1 38.9 95.0 49.7 58.3 3.5 1.4 (5) 68.5 2.4 3.6
Alta padovana 7985 4.4 42.0 86.7 48.3 79.6 2.9 3.7 (32) 66.3 8.1 12.3
Este 5596 5.5 20.0 75.0 66.0 70.8 3.1 2.8 (16) 59.6 4.8 8.3
Lanciano 11,692 9.2 23.3 65.7 35.1 94.3 3.9 5.1 (57) 40.7 4.6 10.6
Padova 10,095 4.9 56.9 77.4 51.7 88.7 3.7 6.3 (60) 74.8 13.0 17.5
Reggio Emilia 3271 6.5 40.6 95.5 42.1 70.6 4.3 5.4 (17) 66.9 8.0 11.3
Rovigo 6727 5.1 32.4 92.9 61.9 49.0 3.6 4.4 (25) 70.8 7.4 10.5
Teramo 7498 7.8 40.7 36.5 26.8 89.6 3.6 3.2 (25) 46.4 3.8 8.1
Torino 12,332 5.9 23.8 91.6 59.1 71.4 3.9 7.0 (84) 65.3 11.4 17.5
Val Camonica 4235 5.0 46.2 79.8 44.6 93.1 3.4 2.9 (13) 65.9 4.7 6.8
Total age standardised 72,869 5.9 36.5 79.6 48.5 76.6 3.6 4.2 (334) 62.5 6.8 10.7
Total not standardised 6.1 34.7 74.5 48.8 80.6 3.6 4.6 (334) 58.9 7.5 12.6
Standard deviation
between statistical
units (programme/age
group combinations)
574 (mean
1214)
2.4 13.9 20.6 17.0 14.6 1.4 3.6 12.8 5.0 7.2
HPVZ human papillomavirus; PPVZ positive predictive value.
Except otherwise specified values are age standardised assuming equal number of women in all age groups.
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Fig. 1. Italian protocol for HPV-based screening. HPVZ human papillomavirus.
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test).
- The overall detection of CIN2þ among HPVþ women as a
function of the proportion of CIN2þ detected by immedi-
ate colposcopy referral in that programme. This latter
proportion comes near to the sensitivity of cytology for
CIN2þ, except for lesions missed on both occasions. The
prevalence of CIN2þ among HPV-infected women in strata
of age and screening history is stable [27] and, therefore,
overall age-adjusted detection of CIN2þ among
HPVþ women can be considered a proxy of the sensitivity
of the entire process and it shows whether it is a function of
the sensitivity of immediate triage. We also studied the
overall CIN2þ detection as a function of immediate referral
to colposcopy.
- The overall positive predictive value (PPV) for CIN2þ of
colposcopy referral (either immediate or after 1 year) both
as a function of the positivity rate and of sensitivity of
cytology.
Adjusted risk differences were obtained from additive
regression models assuming binomial distribution of
errors. Additive (linear) models were used as they are
more easily interpretable and more a priori plausible
than multiplicative (logarithmic) models. The direction
and statistical significance of associations and goodness
of fit did not vary in any case by model (data not
shown). Clustering of women was taken into account by
using generalised estimation equations [28]. All models
were adjusted by 5-year age group and compliance
to immediate colposcopy (done because cytology was
abnormal); 1-year HPV retesting; and delayed colpos-
copy in persistently HPVþ women. Compliances to
colposcopy were not available by age group and there-
fore we used the centre-specific raw value for all age
groups of the same centre. Statistical analyses were
performed using SAS version 9.2 and STATA version
14.3. Results
We included 72,869 women. Table 1 shows age-stand-
ardised (assuming equal size of each age group) values
of selected screening features of the 10 programmes
included in the analysis. On average 5.9% of screened
women were HPVþ and among them 36.5% were
directly referred to immediate triage. Such proportion
varied between programmes from 20.0% to 56.9%. The
remaining 63.5% of HPVþ women were referred to
delayed triage. Eighty percent of them complied and
48.5% of compliers were still HPVþ. As a result of the
entire screening programme (phases 1 þ 2) 3.6% of
screened women were referred to colposcopy and 4.2 per
1000 had CIN2þ detected. Referral and detection of
CIN2þ among HPVþ women were 62.5% and 6.8%
respectively. Some 76.6% of CIN2þ was detected at
immediate colposcopy (range across programmes:
49.0%e94.3%). Overall PPV for CIN2þ of colposcopy
referral was 10.7%. Both compliance to immediate col-
poscopy and to delayed colposcopy was >92% in all
programmes except in Lanciano (83.2% for immediate
and 59.6% for delayed colposcopy) and Teramo (53.7%
and 45.3%, respectively).
Table 2 shows adjusted regression-estimated risk
differences for selected end-points and explanatory
variables. An absolute increase in direct referral to col-
poscopy of 10 absolute percent points (e.g. from 25% to
35%) increased the overall referral by 4.2% (95% CI:
3.3%e5.1%). The proportion of CIN2þ detected by
immediate colposcopy was weakly positively associated
with overall detection of CIN2þ among HPVþ women
but the proportion of HPVþ women immediately
referred to colposcopy was not. An increase of 10 ab-
solute percent points in the proportion of CIN2þ
detected by immediate colposcopy was estimated to
Table 2
Regression-estimated risk difference and corresponding 95% confidence intervals (CIs) by selected end-points and explanatory variables, Italy,
2012e2014.
End-point and explanatory variable Difference (95% CI)
Overall referral to colposcopy for a 10% absolute increase in the proportion of HPVþ women immediately
referred to colposcopy
4.2% (3.3% to 5.1%)
Overall detection of CIN2þ for a 10% absolute increase of the proportion of CIN2þ detected by immediate
referral
1.1% (0.1% to 2.0%)
Overall detection of CIN2þ for a 10% absolute increase of the proportion of HPVþ women immediately
referred to colposcopy
0.4% (e0.5% to 1.2%)
Overall PPV for CIN2þ for a 10% absolute increase of the proportion of HPVþ women immediately
referred to colposcopy
e0.2% (e1.4% to 1.2%)
Overall PPV for CIN2þ for a 10% absolute increase of the proportion of CIN2þ detected by immediate
referral
1.4% (e0.1% to 2.9%)
Probability of being HPVþ at 1-year HPV re-testing for a 10% absolute increase of the proportion of
HPVþ women immediately referred to colposcopy
e3.2% (e5.0% to e1.4%)
HPVZ human papillomavirus; PPVZ positive predictive value.
Differences in end-points are for an increase of 10 absolute percent points (e.g. from 25% to 35%) of the explanatory variable.
Adjusted by 5-year age group, compliance to 1-year HPV retesting, to immediate colposcopy (because of abnormal cytology) and to colposcopy at
1 year (because of persistent HPV infection).
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overall detection of CIN2þ among HPVþ women. An
increase of 10 absolute percent points in immediate
referral was not associated with overall detection of
CIN2þ among HPVþ women (0.4%; e0.5% to 1.2%).
Overall PPV for CIN2þ of colposcopy referral was not
associated with either immediate triage sensitivity or
immediate colposcopy referral. Finally, the probability
of being HPVþ at 1-year HPV retesting slightly but
significantly decreased (e3.2%; CI: e5.0% to e1.4%) for
a 10 absolute percent points increase in immediate col-
poscopy referral.
4. Discussion
4.1. Effect of referral rate and sensitivity of the triage test
on those of the entire triage process
The proportion of HPVþ women judged to have
abnormal cytology and thus referred for immediate
colposcopy varied substantially among Italian screening
programmes because of different thresholds applied in
interpretation. Indeed, also the proportion of CIN2þ
detected by immediate colposcopy varied among pro-
grammes suggesting variability in the sensitivity of
cytology. Beyond cytology, our present study is there-
fore representative of any scenario in which any type of
triage test with different threshold and sensitivity were
used. There is therefore the possibility to assess the effect
of this variability on overall referral to colposcopy,
sensitivity for CIN2þ and PPV resulting from the entire
process.
Our results show that, in a protocol that includes 1-
year repeat HPV testing in women initially triage-
negative, moving from an immediate triage test that
classifies only a small proportion of women as positive
to another triage test that classifies a high proportion of
women as positive has a limited effect on the finalreferral of the overall triage process (therefore on
resource consumption and on efficiency). An increase in
10 absolute percent points in immediate triage results in
only 4.2 absolute percent points in the latter. In the Vrije
Universiteit Medical Centre-Saltro laboratory popula-
tion-based cervical screening (VUSA)-screen cohort
study [29], stand-alone cytology and cytology plus 16/18
genotyping cotesting as immediate triage tests entailed
21.6% and 43.4% immediate referral respectively (a two-
fold increase) but the overall referral with 1-year HPV
repeat, was 65.7% and 72.5% respectively (just a 11%
increase). Variation in overall referral could be larger if
triage test negativity is associated with HPV infection
clearance because in such a case fewer triage-negative
women would be HPVþ at repeat. In our study the
probability of being positive at 1-year HPV retesting
decreased only marginally with the increase of immedi-
ate referral, suggesting that this possibility is small with
cytology. Clearance, however, would be higher in
women positive for non-16 genotypes [30] and, possibly,
in p16 negative women. Nevertheless, the mentioned
association should be very strong in order to have a
substantial effect on the overall screening process.
We also found a very weak relationship between the
proportion of CIN2þ detected by immediate colposcopy
and overall age-adjusted detection of CIN2þ among
HPVþ women suggesting that the overall sensitivity of
the entire screening process was little affected by the
sensitivity of immediate triage. This observation is
consistent with the hypothesis that most lesions missed
by cytology at baseline are detected at HPV retesting.
Regression of CIN2þ in the 1-year interval could explain
their small increase when cytology’s sensitivity is higher.
In the VUSA-screen study [29] stand-alone cytology
had 62.7% sensitivity for CIN2þ among HPVþ women
and cotesting by cytology plus 16/18 genotyping
81.5% sensitivity. However, after 1-year repeat of HPV
testing the estimated overall sensitivity was very similar:
G. Ronco et al. / European Journal of Cancer 68 (2016) 148e15515498.6% and 100% respectively. We found no significant
association between overall CIN2þ detection and the
proportion of HPVþ women immediately referred to
colposcopy.
4.2. Strengths and limitations
Our results are based on a survey of routine imple-
mentation of HPV-based screening in nearly 73,000
women. They combine, therefore, high real-life repre-
sentativeness with strong statistical power.
In principle, local conditions associated to higher or
lower CIN2þ detection (e.g. previous screening history
of the population, quality of colposcopy or broader
criteria of interpretation of histology) could have acted as
confounders if also associated with the sensitivity of
cytology or with the proportion of HPVþ women
directly referred to colposcopy. Such variables were not
measurable in our study. However, to obscure a large
positive effect of the immediate triage test’s sensitivity on
the overall CIN2þ detection they should have acted as
negative confounders, that is, higher sensitivity of his-
tology interpretation should have been strongly associ-
ated with lower sensitivity of cytology, which is rather
implausible. It must also be kept in mind that we included
only women at their first screen with HPV. In POBAS-
CAM and NTCC the proportion of HPVþ women was
about halved at the second round with HPV [31].
Therefore the overall referral to colposcopy is expected to
drop from the second round with HPV.
4.3. Implications for the Italian screening programme
A high variability in the interpretation of triage cytology
was observed. High variability in referral to colposcopy
by cytology was observed in the past among Italian re-
gions [24,25] and even more among EU countries [32].
In Italy cytology variability was progressively reduced
by intensive educational activity of standardisation
[24,25] that will now focus on triage cytology in HPV-
based screening.
It is, however, reassuring that subjectivity in cytology
interpretation has little impact: despite large variation in
immediate referral, overall referral was stably around
3.6%. This value happens to coincide with the overall
referral (3.5%) we assumed for colposcopy referral at the
first round with HPV when we estimated the costs of the
future HPV-based screening in Italy and the corre-
sponding savings compared to cytology [26]. Also
CIN2þ detection was relatively stable showing that
repeating the HPV test acts as a safety net for variations
in cytology interpretation.
4.4. Implications for HPV-based screening algorithms
Our results indirectly suggest that replacing cytology
with another triage test without changing the remainingof the algorithm (HPV retesting at 1 year in triage-
negative women) is likely to have little effect on resource
consumption and overall screening sensitivity.
Positivity at HPV repeat largely depends on the in-
terval before HPV retesting. Overall referral can there-
fore be reduced by prolonging the interval between HPV
tests. Longer intervals obviously entail the risk that a
CIN2þ missed by the immediate triage test may prog-
ress into invasive carcinoma before HPV retesting. This
risk is clearly a function of the cross-sectional sensitivity
of the triage test(s) without HPV repeat and, therefore,
the use of an extremely sensitive triage test (or combi-
nation of tests) could be efficient even if it leads to high
immediate referral provided that the extra sensitivity is
accompanied by a prolongation of the interval before
HPV repeat.
This study shows that routine data collected for
screening monitoring can be used for research purposes
and can provide relevant information in order to opti-
mise screening methods.
Conflict of interest statement
GR, MZa, SF, ST, AC, MC, AD, FC, NS and MZo
have no conflicts of interest to declare.
PGR, as former principal investigator of an inde-
pendent study, funded by the Italian Ministry of Health,
data owner, made agreements with Roche diagnostics,
Hologic Genprobe, Abbott, and Qiagen to obtain re-
agents at reduced price or for free.
Funding
This study was funded by the Italian Ministry of
Health (finalised funds Center for Disease Control 2013
decision no. 136) by the European Union (CoHeahr
project, FP7 grant agreement n HEALTH-F3-
2013e603019) and by the Associazione Italiana per la
Ricerca sul Cancro (AIRC, Project IG14119).
The funders had no role in study design, data collec-
tion, data analysis, data interpretation or writing of the
report, nor in the decision to submit for publication.
References
[1] Arbyn M, Ronco G, Anttila A, Meijer CJLM, Poljak M,
Ogilvie G, et al. Evidence regarding human papillomavirus testing
in secondary prevention of cervical cancer. Vaccine 2012 Nov 20;
30(Suppl. 5):F88e99.
[2] Ronco G, Dillner J, Elfstro¨m KM, Tunesi S, Snijders PJF,
Arbyn M, et al. Efficacy of HPV-based screening for prevention
of invasive cervical cancer: follow-up of four European rando-
mised controlled trials. Lancet 2014;383(9916):524e32.
[3] Naucler P, Ryd W, To¨rnberg S, Strand A, Wadell G, Elfgren K,
et al. Human papillomavirus and Papanicolaou tests to screen for
cervical cancer. N Engl J Med 2007 Oct 18;357(16):1589e97.
[4] Kitchener HC, Almonte M, Thomson C, Wheeler P, Sargent A,
Stoykova B, et al. HPV testing in combination with liquid-based
G. Ronco et al. / European Journal of Cancer 68 (2016) 148e155 155cytology in primary cervical screening (ARTISTIC): a rando-
mised controlled trial. Lancet Oncol 2009;10:672e82.
[5] Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ,
Bulkmans NWJ, Heideman DAM, et al. Human papillomavirus
testing for the detection of high-grade cervical intraepithelial
neoplasia and cancer: final results of the POBASCAM rando-
mised controlled trial. Lancet Oncol 2012;13:78e88.
[6] Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK,
Schiffman M, et al. 2012 updated consensus guidelines for the
management of abnormal cervical cancer screening tests and
cancer precursors. Obst Gynecol 2013;121:829e46.
[7] Bergeron C, Giorgi-Rossi P, Cas F, Schiboni ML, Ghiringhello B,
Dalla Palma P, et al. Informed cytology for triaging HPV-positive
women: substudy nested in theNTCC randomized controlled trial. J
Natl Cancer Inst 2015;107(12). http://dx.doi.org/10.1093/jn-
ci/dju423. dju423.
[8] Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N,
Tarkkanen J, Laurila P, et al. Age-specific evaluation of primary
human papillomavirus screening vs conventional cytology in a
randomized setting. J Natl Cancer Inst 2009;101:1612e23.
[9] Castle PE, Stoler MH, Wright TC, Sharma A, Wright TL,
Behrens CM. Performance of carcinogenic human papillomavirus
(HPV) testing and HPV16 or HPV18 genotyping for cervical
cancer screening of women aged 25 years and older: a subanalysis
of the ATHENA study. Lancet Oncol 2011;12:880e90.
[10] Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Gillio-
Tos A, De Marco L, et al. Use of p16-INK4A overexpression to
increase the specificity of human papillomavirus testing: a nested
substudy of the NTCC randomised controlled trial. Lancet Oncol
2008;9:937e45.
[11] Carozzi F, Gillio-Tos A, Confortini M, Del Mistro A, Sani C, De
Marco L, et al. Risk of high-grade cervical intraepithelial
neoplasia during follow-up in HPV-positive women according to
baseline p16-INK4A results: a prospective analysis of a nested
substudy of the NTCC randomised controlled trial. Lancet Oncol
2013;14:168e76.
[12] Petry KU, Schmidt D, Scherbring S, Luyten A, Reinecke-
Lu¨thge A, Bergeron C, et al. Triaging Pap cytology negative, HPV
positive cervical cancer screening results with p16/Ki-67 Dual-
stained cytology. Gynecol Oncol 2011;121:505e9.
[13] Wentzensen N, Fetterman B, Castle PE, Schiffman M, Wood SN,
Stiemerling E, et al. p16/Ki-67 dual stain cytology for detection of
cervical precancer in HPV-positive women. J Natl Cancer Inst
2015 Sept 15;107(12). http://dx.doi.org/10.1093/jnci/djv257. pii:
djv257. Print 2015 Dec.
[14] Uijterwaal MH, Polman NJ, Witte BI, van Kemenade FJ,
Rijkaart D, Berkhof J, et al. Triaging HPV-positive women with
normal cytology by p16/Ki-67 dual-stained cytology testing:
baseline and longitudinal data. Int J Cancer 2015 May 15;136(10):
2361e8. http://dx.doi.org/10.1002/ijc.29290 [Epub 2014 Nov 6].
[15] De Strooper LMA, Meijer CJLM, Berkhof J, Hesselink AT,
Snijders PJF, Steenbergen RDM, et al. Methylation analysis of the
FAM19A4 gene in cervical scrapes is highly efficient in detecting
cervical carcinomas and advancedCIN2/3 lesions. Cancer PrevRes
(Phila) 2014 Dec;7:1251e7. http://dx.doi.org/10.1158/1940-
6207.CAPR-14-0237 [Epub 2014 Oct 3].
[16] De Strooper LMA, Hesselink AT, Berkhof J, Meijer CJLM,
Snijders PJF, Steenbergen RDM, et al. Combined CADM1/MAL
methylation and cytology testing for colposcopy triage of high-
risk HPV-positive women. Cancer Epidemiol Biomarkers Prev
2014 Sep;23(9):1933e7. http://dx.doi.org/10.1158/1055-9965.EPI-
14-0347 [Epub 2014 Jun 24].
[17] Verhoef VMJ, Bosgraaf RP, van Kemenade FJ, Rozendaal L,
Heideman DAM, Hesselink AT, et al. Triage by methylation-marker testing versus cytology in women who test HPV-positive
on self-collected cervicovaginal specimens (PROHTECT-3): a
randomised controlled non-inferiority trial. Lancet Oncol 2014
Mar;15(3):315e22. http://dx.doi.org/10.1016/S1470-2045(14)
70019-1 [Epub 2014 Feb 13].
[18] Mirabello L, Sun C, Ghosh A, Rodriguez AC, Schiffman M,
Wentzensen N, et al. Methylation of human papillomavirus type
16 genome and risk of cervical precancer in a Costa Rican pop-
ulation. J Natl Cancer Inst 2012 Apr 4;104(7):556e65. http:
//dx.doi.org/10.1093/jnci/djs135 [Epub 2012 Mar 23].
[19] Wentzensen N, Sun C, Ghosh A, Kinney W, Mirabello L,
Wacholder S, et al. Methylation of HPV18, HPV31, and HPV45
genomes and cervical intraepithelial neoplasia grade 3. JNatlCancer
Inst 2012 Nov 21;104(22):1738e49. http://dx.doi.org/10.1093/jn-
ci/djs425 [Epub 2012 Oct 23].
[20] Vasiljevic N, Scibior-Bentkowska D, Brentnall A, Cuzick J,
Lorincz A. A comparison of methylation levels in HPV18,
HPV31 and HPV33 genomes reveals similar associations with
cervical precancers. J Clin Virol 2014 Mar;59(3):161e6. http:
//dx.doi.org/10.1016/j.jcv.2013.12.014 [Epub 2014 Jan 8].
[21] ValdezM, JeronimoJ,Bansil P,QiaoY-L,ZhaoF-H,ChenW, et al.
Effectiveness of novel, lower cost molecular human papillomavirus-
based tests for cervical cancer screening in rural China. Int J Cancer
2016 Mar 15;138:1453e61. http://dx.doi.org/10.1002/ijc.29877
[Epub ahead of print].
[22] Wentzensen N, Schiffman M, Palmer T, Arbyn M. Triage of HPV
positive women in cervical cancer screening. J Clin Virol 2016;
76(Suppl. 1):S49e55.
[23] Ronco G, Giorgi Rossi P, Giubilato P, Del Mistro A, Zappa M,
Carozzi F, et al. A first survey of HPV-based screening in routine
cervical cancer screening in Italy. Epidemiol Prev 2015 MayeJun;
39(3 Suppl. 1):77e83.
[24] Ronco G, Iossa A, Naldoni C, Pilutti S, Anghinoni E, Zappa M,
et al. A first survey of organized cervical cancer screening pro-
grams in Italy. Tumori 1998;84:624e30.
[25] Ronco G, Giubilato P, Carozzi F, Maia G, Giorgi Rossi P,
Zappa M, et al. Extension of organized cervical cancer screening
programmes in Italy and their process indicators, 2011e2012
activity. Epidemiol Prev 2015 MayeJun;39(3 Suppl. 1):61e76.
[26] Ronco G, Biggeri A, Confortini M, Naldoni C, Segnan N,
Sideri M, et al. Health technology assessment report: HPV DNA
based primary screening for cervical cancer precursors. Epidemio
Prev 2012;36(3e4 Suppl. 1):1e72 [Italian].
[27] Giorgi-Rossi P, Franceschi S, Ronco G. HPV prevalence and
accuracy of HPV testing to detect high-grade cervical intra-
epithelial neoplasia. Int J Cancer 2012 Mar 2105;130(6):1387e94.
[28] Liang KY, Zeger SL. Longitudinal data analysis using generalized
linear models. Biometrika 1986;73:13e22.
[29] Rijkaart DC, Berkhof J, van Kemenade FJ, Coupe VMH,
Hesselink AT, Rozendaal L, et al. Evaluation of 14 triage stra-
tegies for HPV DNA-positive women in population-based cervi-
cal screening. Int J Cancer 2012;130:602e10.
[30] Richardson H, Kelsall G, Tellier P, Voyer H, Abrahamowicz M,
Ferenczy A, et al. The natural history of type-specific human
papillomavirus infections in female university students. Cancer
Epidemiol Biomarkers Prev 2003 Jun;12(6):485e90.
[31] Veldhuijzen NJ, Berkhof J, Gillio-Tos A, De Marco L, Carozzi F,
Del Mistro A, et al. The age distribution of type-specific high-risk
human papillomavirus incidence in two population-based
screening trials. Cancer Epidemiol Biomarkers Prev 2015;24:
111e8.
[32] Ronco G, van Ballegooijen M, Becker N, Chil A, Fender M,
Giubilato P, et al. Process performance of cervical screening
programmes in Europe. Eur J Cancer 2009;45:2659e70.
